REG - AstraZeneca PLC - FDA accepts Dato-DXd BLA for breast cancer

AstraZenecaAnnouncement

02/04/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240402:nRSB8968Ia&default-theme=true

RNS Number : 8968I  AstraZeneca PLC  02 April 2024

2 April 2024

 

Datopotamab deruxtecan Biologics License Application accepted in the US for
patients with previously treated metastatic HR-positive, HER2-negative breast
cancer

 

Application based on results from the TROPION-Breast01 Phase III trial

 

Additional BLA under review in the US for AstraZeneca and Daiichi Sankyo's
datopotamab deruxtecan for patients with advanced nonsquamous non-small cell
lung cancer

 

AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for
datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the
treatment of adult patients with unresectable or metastatic hormone receptor
(HR)-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who
have received prior systemic therapy for unresectable or metastatic disease.
The Prescription Drug User Fee Act date, the US Food and Drug Administration
(FDA) action date for its regulatory decision, is during the first quarter of
2025.

 

The BLA is based on results from the pivotal TROPION-Breast01 Phase III trial
in which datopotamab deruxtecan demonstrated a statistically significant and
clinically meaningful improvement for the dual primary endpoint of
progression-free survival (PFS) compared to investigator's choice of
chemotherapy in patients with unresectable or metastatic HR-positive,
HER2-negative breast cancer previously treated with endocrine-based therapy
and at least one systemic therapy. For the dual primary endpoint of overall
survival (OS), interim results numerically favoured datopotamab deruxtecan
over chemotherapy but were not mature at the time of data cut-off. The trial
is ongoing and OS will be assessed at future analyses.

 

Datopotamab deruxtecan is a specifically engineered TROP2-directed DXd
antibody drug conjugate (ADC) discovered by Daiichi Sankyo and being jointly
developed by AstraZeneca and Daiichi Sankyo.

 

Susan Galbraith, Executive Vice President, Oncology R&D, AstraZeneca,
said: "Despite marked progress in the treatment of HR-positive, HER2-negative
breast cancer, most patients with advanced disease develop endocrine
resistance and face the prospect of one or several lines of chemotherapy. If
approved, datopotamab deruxtecan has the potential to provide these patients
an efficacious and better tolerated alternative to conventional chemotherapy."

 

Ken Takeshita, MD, Global Head, R&D, Daiichi Sankyo, said: "The FDA's
acceptance of the BLA brings us closer to providing patients with previously
treated HR-positive, HER2-negative breast cancer an alternative option to
conventional chemotherapy earlier in the metastatic setting. Following our
recently accepted application for advanced nonsquamous non-small cell lung
cancer in the US, along with additional regulatory reviews underway in China,
the EU, Japan and other regions, we are working swiftly to bring datopotamab
deruxtecan as a potential new treatment option to patients around the world."

 

Results from TROPION-Breast01
(https://www.astrazeneca.com/media-centre/press-releases/2023/datopotamab-deruxtecan-significantly-extended-progression-free-survival-vs-chemotherapy-in-tropion-breast01-phase-iii-trial.html)
were presented during a Presidential Symposium at the 2023 European Society
for Medical Oncology Congress and in an oral presentation at the 2023 San
Antonio Breast Cancer Symposium.

 

The safety profile of datopotamab deruxtecan was consistent with that observed
in other ongoing trials with no new safety concerns identified.

 

An additional BLA for datopotamab deruxtecan based on results from the pivotal
TROPION-Lung01 Phase III trial is under review in the US for the treatment of
adult patients with locally advanced or metastatic nonsquamous non-small cell
lung cancer (NSCLC) who have received prior systemic therapy. Additional
regulatory submissions for datopotamab deruxtecan in lung and breast cancer
are underway globally.

 

Notes

 

HR-positive breast cancer

More than 275,000 breast cancer cases were diagnosed in the US in 2022.(1)
HR-positive, HER2-negative breast cancer is the most common subtype,
accounting for more than 65% of diagnosed cases.(2) Breast cancer is
considered HR-positive, HER2-negative when tumours test positive for oestrogen
and/or progesterone hormone receptors and negative for HER2 (measured as HER2
score of IHC 0, IHC 1+ or IHC 2+/ISH-).(2,3) Standard initial treatment for
this subtype of breast cancer is endocrine therapy but most patients with
advanced disease will develop resistance, underscoring the need for additional
options.(4,5)

( )

TROP2 is a protein broadly expressed in HR-positive, HER2-negative breast
cancer and is associated with increased tumour progression and poor
survival.6,7

( )

TROPION-Breast01

TROPION-Breast01 is a global, randomised, multicentre, open-label Phase III
trial evaluating the efficacy and safety of datopotamab deruxtecan versus
investigator's choice of single-agent chemotherapy (eribulin, capecitabine,
vinorelbine or gemcitabine) in patients with unresectable or metastatic
HR-positive, HER2-negative (IHC 0, IHC 1+ or IHC 2+/ISH-) breast cancer who
have progressed on and are not suitable for endocrine therapy per investigator
assessment and have received at least one additional systemic therapy for
unresectable or metastatic disease.

 

The dual primary endpoints of TROPION-Breast01 are PFS as assessed by blinded
independent central review (BICR) and OS. Key secondary endpoints include
objective response rate, duration of response, investigator-assessed PFS,
disease control rate, time to first subsequent therapy and safety.
TROPION-Breast01 enrolled more than 700 patients in Africa, Asia, Europe,
North America and South America. For more information visit ClinicalTrials.gov
(https://clinicaltrials.gov/ct2/show/NCT05104866?term=TROPION-Breast01&draw=2&rank=1)
.

( )

Datopotamab deruxtecan (Dato-DXd)

Datopotamab deruxtecan (Dato-DXd) is an investigational TROP2-directed ADC.
Designed using Daiichi Sankyo's proprietary DXd ADC Technology, datopotamab
deruxtecan is one of six DXd ADCs in the oncology pipeline of Daiichi Sankyo,
and one of the most advanced programmes in AstraZeneca's ADC scientific
platform. Datopotamab deruxtecan is comprised of a humanised anti-TROP2 IgG1
monoclonal antibody, developed in collaboration with Sapporo Medical
University, attached to a number of topoisomerase I inhibitor payloads (an
exatecan derivative, DXd) via tetrapeptide-based cleavable linkers.

 

A comprehensive global clinical development programme is underway with more
than 20 trials evaluating the efficacy and safety of datopotamab deruxtecan
across multiple cancers, including NSCLC, triple-negative breast cancer (TNBC)
and HR-positive, HER2-negative breast cancer.

 

Daiichi Sankyo collaboration

AstraZeneca and Daiichi Sankyo entered into a global collaboration to jointly
develop and commercialise Enhertu in March 2019
(https://www.astrazeneca.com/media-centre/press-releases/2019/astrazeneca-and-daiichi-sankyo-enter-collaboration-for-novel-her-2-targeting-antibody-drug-conjugate.html#modal-historic-confirmation)
and datopotamab deruxtecan in July 2020
(https://www.astrazeneca.com/media-centre/press-releases/2020/astrazeneca-and-daiichi-sankyo-enter-collaboration-to-develop-and-commercialise-new-antibody-drug-conjugate.html#modal-historic-confirmation)
, except in Japan where Daiichi Sankyo maintains exclusive rights for each
ADC. Daiichi Sankyo is responsible for the manufacturing and supply of Enhertu
and datopotamab deruxtecan.

 

AstraZeneca in breast cancer

Driven by a growing understanding of breast cancer biology, AstraZeneca is
starting to challenge, and redefine, the current clinical paradigm for how
breast cancer is classified and treated to deliver even more effective
treatments to patients in need - with the bold ambition to one day eliminate
breast cancer as a cause of death.

 

AstraZeneca has a comprehensive portfolio of approved and promising compounds
in development that leverage different mechanisms of action to address the
biologically diverse breast cancer tumour environment.

 

With Enhertu (trastuzumab deruxtecan), a HER2-directed ADC, AstraZeneca and
Daiichi Sankyo are aiming to improve outcomes in previously treated
HER2-positive and HER2-low metastatic breast cancer and are exploring its
potential in earlier lines of treatment and in new breast cancer settings.

 

In HR-positive breast cancer, AstraZeneca continues to improve outcomes with
foundational medicines Faslodex and Zoladex (goserelin) and aims to reshape
the HR-positive space with first-in-class AKT inhibitor, Truqap, and
next-generation SERD and potential new medicine camizestrant. AstraZeneca is
also collaborating with Daiichi Sankyo to explore the potential of
TROP2-directed ADC, datopotamab deruxtecan, in this setting.

 

PARP inhibitor Lynparza (olaparib) is a targeted treatment option that has
been studied in early and metastatic breast cancer patients with an inherited
BRCA mutation. AstraZeneca with MSD (Merck & Co., Inc. in the US and
Canada) continue to research Lynparza in these settings and to explore its
potential in earlier disease.

 

To bring much-needed treatment options to patients with TNBC, an aggressive
form of breast cancer, AstraZeneca is evaluating the potential of datopotamab
deruxtecan alone and in combination with immunotherapy Imfinzi (durvalumab),
Truqap in combination with chemotherapy, and Imfinzi in combination with
other oncology medicines, including Lynparza and Enhertu.

 

AstraZeneca in oncology

AstraZeneca is leading a revolution in oncology with the ambition to provide
cures for cancer in every form, following the science to understand cancer and
all its complexities to discover, develop and deliver life-changing medicines
to patients.

 

The Company's focus is on some of the most challenging cancers. It is through
persistent innovation that AstraZeneca has built one of the most diverse
portfolios and pipelines in the industry, with the potential to catalyse
changes in the practice of medicine and transform the patient experience.

 

AstraZeneca has the vision to redefine cancer care and, one day, eliminate
cancer as a cause of death.

 

AstraZeneca
AstraZeneca (LSE/STO/Nasdaq: AZN) is a global, science-led biopharmaceutical
company that focuses on the discovery, development, and commercialisation of
prescription medicines in Oncology, Rare Diseases, and BioPharmaceuticals,
including Cardiovascular, Renal & Metabolism, Respiratory & Immunology
and Vaccines & Immune Therapies. Based in Cambridge, UK, AstraZeneca
operates in over 100 countries and its innovative medicines are used by
millions of patients worldwide. Please visit astrazeneca.com
(https://www.astrazeneca.com/) and follow the Company on social media
@AstraZeneca (https://www.linkedin.com/company/astrazeneca/) .

 
Contacts

For details on how to contact the Investor Relations Team, please click here
(https://www.astrazeneca.com/investor-relations.html#Contacts) . For Media
contacts, click here (https://www.astrazeneca.com/media-centre/contacts.html)
.

 

References

1.   World Health Organization. Global Cancer Observatory: United States of
America. Available at:
https://gco.iarc.who.int/media/globocan/factsheets/populations/840-united-states-of-america-fact-sheet.pdf
(https://gco.iarc.who.int/media/globocan/factsheets/populations/840-united-states-of-america-fact-sheet.pdf)
. Accessed April 2024.

2.   National Cancer Institute. SEER cancer stat facts: female breast cancer
subtypes. Available at:
https://seer.cancer.gov/statfacts/html/breast-subtypes.html
(https://seer.cancer.gov/statfacts/html/breast-subtypes.html) . Accessed April
2024.

3.   Iqbal N, et al. Human Epidermal Growth Factor Receptor 2 (HER2) in
Cancers: Overexpression and Therapeutic Implications. Mol Biol Int.
2014;852748.

4.   Lin M, et al. Comparative Overall Survival of CDK4/6 Inhibitors Plus
Endocrine Therapy vs. Endocrine Therapy Alone for Hormone receptor-positive,
HER2-negative metastatic breast cancer. J Cancer. 2020; 10.7150/jca.48944.

5.   Lloyd MR, et al. Mechanisms of Resistance to CDK4/6 Blockade in
Advanced Hormone Receptor-positive, HER2-negative Breast Cancer and Emerging
Therapeutic Opportunities. Clin Cancer Res. 2022; 28(5): 821-30.

6.   Goldenberg D, et al. The emergence of trophoblast cell-surface antigen
2 (TROP-2) as a novel cancer target. Oncotarget. 2018;9(48): 28989-29006.

7.   Vidula N, et al. Sacituzumab govitecan: Antibody-drug conjugate in
triple negative breast cancer and other solid tumours. Breast Cancer Res
Treat. 2022 Aug;194(3): 569-575.

 

Adrian Kemp
Company Secretary
AstraZeneca PLC

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  MSCZZGGDVMFGDZM